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Abstract
Background: The Karnofsky Performance Status (KPS) is a gold standard scale. The Thorne-
modified KPS (TKPS) focuses on community-based care and has been shown to be more relevant
to palliative care settings than the original KPS. The Australia-modified KPS (AKPS) blends KPS and
TKPS to accommodate any setting of care.
Methods: Performance status was measured using all three scales for palliative care patients
enrolled in a randomized controlled trial in South Australia. Care occurred in a range of settings.
Survival was defined from enrollment to death.
Results: Ratings were collected at 1600 timepoints for 306 participants. The median score on all
scales was 60. KPS and AKPS agreed in 87% of ratings; 79% of disagreements occurred within 1
level on the 11-level scales. KPS and TKPS agreed in 76% of ratings; 85% of disagreements occurred
within one level. AKPS and TKPS agreed in 85% of ratings; 87% of disagreements were within one
level. Strongest agreement occurred at the highest levels (70–90), with greatest disagreement at
lower levels (≤40). Kappa coefficients for agreement were KPS-TKPS 0.71, KPS-AKPS 0.84, and
AKPS-TKPS 0.82 (all p < 0.001). Spearman correlations with survival were KPS 0.26, TKPS 0.27 and
AKPS 0.26 (all p < 0.001). AKPS was most predictive of survival at the lower range of the scale. All
had longitudinal test-retest validity. Face validity was greatest for the AKPS.
Conclusion: The AKPS is a useful modification of the KPS that is more appropriate for clinical
settings that include multiple venues of care such as palliative care.
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Palliative care clinicians are increasingly using change in
performance status as a flag for likelihood of need for
services, timing of interventions, and as an outcome
measurement for clinical programs and research [1-3].
The Karnofsky Performance Scale (KPS) has been used as
an assessment tool for performance status in oncology
since 1948 [4]. It is commonly regarded as the gold stand-
ard measurement of performance status in cancer[2,3].
The KPS scale assesses three dimensions of health status –
activity, work and self-care – and can be administered by
any healthcare professional for a quick assessment of gen-
eral functioning and survival [5].
The original KPS is an ordered categorical scale with 11
levels (Table 1). Extensive psychometric testing provides
evidence of acceptable reliability and validity in patients
with cancer[3,6,7]. The KPS correlates well with physical
functioning, such as walking and stair climbing [7]. It has
been repeatedly demonstrated to be useful in assisting
prognostication [4,8-11]. In an evaluation of predictive
validity, Mor et al found significant correlation between
KPS at initial interview and survival time (r = 0.30, P <
0.001) [6]. When KPS is low it is a sensitive predictor of
poor prognosis, but when high it is a poor cross-sectional
indicator of prognosis [2].
While useful, the original KPS has limitations. It was
based on the models of health service delivery available in
1948, linking performance status with strict recommenda-
tions about where further clinical care should be provided
(Table 1). At KPS 30 and below there are recommenda-
tions for the intensity of clinical care including hospitali-
zation. In particular, the KPS focus on need for
hospitalization and medical intervention limits its appli-
cability in care settings where clinical options extend to
non-hospital-based care directed at support rather than
cure, such as palliative care settings. The language may be
uncomfortable or confusing to nurses and other clinicians
expected to apply the scale to palliative patients for whom
they are caring in home or hospice settings but then
expected to blatantly ignore the KPS recommendations of
hospitalization. Recommendations about place of care
need not be part of the KPS for it to be clinically useful in
the 21st century [3].
These limitations have prompted modifications of the
scale and development of new tools that better reflect clin-
ical functioning and variations in place of care for pallia-
tive care patients. In the late 1990's, Thorne developed a
modified version of the KPS (Thorne-modified Karnofsky
Performance Status, TKPS, Table 1) for use in palliative
home care settings. The TKPS reworded the categories at
Table 1: Comparison of the original Karnofsky Performance Status Scale (KPS), Thorne-modified Karnofsky Performance Status Scale 
(TKPS), and the Australia-modified Karnofsky Performance Status Scale (AKPS). Italicised areas reflect the original KPS instrument.
Score 
(Category)
Original Karnofsky 
(KPS)
Thorne-modified Karnofsky (TKPS) Australia-modified Karnofsky 
(AKPS)
100 (A) Normal; no complaints; no evidence of 
disease.
Normal; no complaints; no evidence of 
disease.
Normal; no complaints; no evidence of 
disease.
90 (A) Able to carry on normal activity; minor signs 
or symptoms.
Able to carry on normal activity; minor signs 
or symptoms.
Able to carry on normal activity; minor signs 
or symptoms.
80 (A) Normal activity with effort; some signs or 
symptoms of disease.
Normal activity with effort; some signs or 
symptoms of disease.
Normal activity with effort; some signs or 
symptoms of disease.
70 (B) Cares for self; unable to carry on normal 
activity or to do active work.
Cares for self; unable to carry on normal 
activity or to do active work.
Cares for self; unable to carry on normal 
activity or to do active work.
60 (B) Requires occasional assistance but is able to 
care for most of his needs.
Requires professional visits less than once 
a week.
Requires occasional assistance but is able to 
care for most of his needs.
50 (B) Requires considerable assistance and frequent 
medical care
Requires professional visits more than 
once a week.
Requires considerable assistance and frequent 
medical care
40 (C) Disabled; requires special care and 
assistance.
In bed more than 50% of the time. In bed more than 50% of the time.
30 (C) Severely disabled; hospitalisation necessary; 
active supportive treatment is necessary.
Almost completely bedfast. Almost completely bedfast.
20 (C) Very sick; hospitalisation necessary; active 
supportive treatment is necessary.
Totally bedfast and requiring extensive 
nursing care by professionals and/or 
family.
Totally bedfast and requiring extensive 
nursing care by professionals and/or 
family.
10 (C) Moribund; fatal processes progressing rapidly. Comatose or barely arousable. Comatose or barely arousable.
0 Dead. Dead. Dead.Page 2 of 12
(page number not for citation purposes)
BMC Palliative Care 2005, 4:7 http://www.biomedcentral.com/1472-684X/4/7the lower end of the KPS scale to correlate with profes-
sional care needs and activity, removing references to
location of care. The TKPS was validated by Nikoletti and
colleagues in a sample of 78 Australian home-hospice
patients [3].
While the TKPS was found to be more applicable for
home-based hospice settings, it was limited in its use for
hospitalized palliative care patients. In response, the orig-
inal KPS and the newer TKPS were melded into a single
scale that accommodated all of the venues of clinical pal-
liative care – the Australia-modified Karnofsky Perform-
ance Status Scale (AKPS, Table 1). In the AKPS, the TKPS
link to health professionals' visits was avoided, favoring a
generic approach focusing on function alone.
We conducted a large randomized controlled trial that
incorporated performance status as a main outcome
measure – the Palliative Care Trial. This study is a 2 × 2 ×
2 factorial cluster randomized controlled trial involving
461 consenting patients and their general practitioners
(GPs) recruited from April 2002 and June 2004. Partici-
pants were randomized to case conferences, GP pain edu-
cation, and patient pain education. Patient participants
were cared for in a variety of clinical settings consistent
with contemporary clinical practice. It was important that
the performance status scale used was appropriate and
carefully validated. The full clinical trial methodology has
been presented elsewhere [1].
The purpose of this current study was to determine the
performance status measure most appropriate for the clin-
ical and research needs of the community based palliative
care service conducting the Palliative Care Trial. The
expected goals were to do the following:
1. To determine if the TKPS and AKPS had similar predic-
tive values for survival as compared with the KPS in a con-
temporary specialized palliative care service that
incorporates a range of clinical settings including acute
hospital care, inpatient hospice, community care, and
aged care facilities;
2. To determine if one version of the KPS instrument was
clearly superior to the others in this setting;
3. If equal, to determine which instrument was most
acceptable to clinical and research staff and easiest to use;
and,
4. To document reliability of the three instruments in the
local clinical setting.
Methods
This current study was an embedded sub-study within the
Palliative Care Trial [1]. It was decided a priori that after
KPS, TKPS and AKPS data were collected from at least 120
participants who exited the trial, a validity assessment of
the scales would be conducted. Based on this analysis all
subsequent Palliative Care Trial assessments would
include only the most reliable of these 3 measures.
Study setting
The trial was set in Adelaide, South Australia and based at
Southern Adelaide Palliative Services. GPs are the primary
point of care for palliative patients. Specialized palliative
care services funded by the state government provide con-
sultative specialist medical and nursing support for GPs
and community nurses. Referrals to the palliative care
service come from health professionals, family and
patients, and nearly all palliative care patients within the
region are referred to the same geographic service. The
indication for, and timing of referral varies; indications
include physical symptom control, and the need for coor-
dinated and multi-disciplinary care. Patients frequently
receive active therapy such as radiotherapy and chemo-
therapy in parallel with palliative care services. The model
of care is consistent with the definition of palliative care
described in the 2004 United States (US) National Con-
sensus Project Clinical Practice Guidelines for Quality Pal-
liative Care [12].
Southern Adelaide Palliative Services is a comprehensive
program with medical specialists, nursing specialists,
social work, inpatient care, community and outpatient
visits, home care, nursing home consultations, a bereave-
ment program, volunteers, and complementary care. Ven-
ues of care include community, acute inpatient, sub-acute
inpatient, inpatient hospice, respite, nursing home, and
hostel settings. There were 1,094 new referrals in 2003,
85% of whom had cancer. The mean time from referral to
death was 119 days with a median of 47 days. Ten percent
of referrals were from GPs, 50% from local hospitals, 20%
from medical specialists, and 10% from district nurses.
Ninety percent of patients spent some time in the hospital
in the last year of life and less than one third spent any
time in the inpatient hospice.
Study participants
All adult patients referred to Southern Adelaide Palliative
Services with any form of pain in the preceding three
months were eligible for the Palliative Care Trial. This def-
inition was very broadly applied and could refer to any
type of pain. This pain could have been temporary and
not related to the predominate illness, but would provide
a reference point for pain assessments during the research
study. Patients who did not live within the geographic
region served by the palliative care service were excluded.Page 3 of 12
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referral were also excluded, since the recruitment process
of consenting both the patient and GP was expected to
take two days. Participants must have been mentally com-
petent at enrollment as documented by a Folstein Mini-
mental Status Examination (MMSE) Score = 24 [13], or
have a GP-identified caregiver or legal healthcare proxy
who could adequately provide informed consent [14].
Patients unwilling to provide their contact information to
the trial staff in order to learn more about the study were
not enrolled. All GPs and GP practices of consenting eligi-
ble patients were eligible. Both patient and GP consent
were required for enrollment and randomization.
Measures
Patient participant functional status was assessed by the
KPS, TKPS and AKPS (Table 1) simultaneously. For those
patients who died during the trial, survival was defined as
time from consent to participate in the trial until death.
Study procedures
KPS, TKPS and AKPS were collected at every clinical
encounter and data collection time point (minimally
baseline and every 2 weeks for the first 12 weeks then
monthly until death or exit from the trial) for the first 300
participants randomized in the trial. Based on our sample
size assumptions and recruitment estimates, this would
provide data for over 120 participants who exited the trial
through either death or withdrawal from the study. Palli-
ative care clinical nurses collected all of the data within
the study. Data collection was incorporated into regular
palliative clinical visits irrespective of location of care
(hospital- or community-based care). In total, 26 full or
part-time nurses collected data.
All clinical nurses participated in training in performance
status assessment. This included at least a 30-minute
review of the scales, data collection forms, and reasons for
using all three measures. In addition, written instructions
were prepared that included a list of example questions
that could be used to determine performance status classi-
fication. Nurses were provided laminated cards with each
Table 2: Baseline participant characteristics
Characteristic Category N %
Gender Male 148 49%
Age (Mean/SD) 71 12%
Marital status Never Married 9 3%
Widowed 69 23%
Divorced/Separated 33 11%
Married/Defacto 190 63%
Caregiver present Has caregiver 277 96%
Accommodation Private residence 271 89%
Nursing home 18 6%
Hostel 4 1%
Hospital 11 4%
Other 2 1%
Living arrangement Lives alone 72 25%
Lives with spouse 173 60%
Other relative lives in household 44 15%
Cancer diagnosis Yes 282 92%
Phase of palliative care Stable 157 60%
Deteriorating 48 18%
Unstable 57 22%
Terminal 1 0%
Pain at present Mean (standard deviation) (2.1)
Usual pain in last 24 hrs (2.1)
Worst pain in last 24 hrs (3.2)Page 4 of 12
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set of study forms. Nurses also underwent more specific
training on data collection methods, the importance of
data quality, communication and research ethics as part of
the Palliative Care Trial [1].
Analysis
Descriptive statistics were used to summarize the partici-
pant population and performance status scores observed.
Agreement between the KPS, TKPS and AKPS was assessed
by a variety of methods. Percentage agreements and disa-
greements were calculated; overall agreement and propor-
tion of disagreements at one, two or three levels on the
scales were reported in the method of Nikoletti et al [3].
Kappa statistics were calculated in order to exclude agree-
ment due to chance. Simple kappa statistics were reported
and subjected to the following interpretation: 0.81 to 1.00
almost perfect agreement, 0.61 to 0.80 substantive agree-
ment, 0.41–0.60 moderate agreement, 0.21–0.40 fair
agreement, 0.00–0.20 slight agreement, and less than
0.00 poor or no agreement [15]. Bland-Altman plots of
the difference between paired scores versus the mean of
the scores were used to assess agreement [16]. The associ-
ation between performance status and survival was deter-
mined using Spearman correlation coefficients [5].
Actuarial survival was estimated using Kaplan-Meier
methods and reported as median (interquartile range
(IQR)) survival [17]. Between group comparisons were
made using the log rank test [18]. All analyses were con-
ducted with the SAS System (Version 9.1, Cary, North
Carolina, USA).
Ethics approval and trial registration
The Palliative Care Trial was approved by all twelve rele-
vant independent Institutional Review Boards (IRBs) and
Human Research and Ethics Committees (HRECs) includ-
ing the Australian Department of Veterans Affairs and
Health Insurance Commission, Canberra, Australia. This
sub-study was included in the approved protocols and
participant consent forms. The Palliative Care Trial is reg-
istered with the ISRCTN – ISRCTN81117481 http://
www.controlled-trials.com/isrctn/trial/81117481/0/
81117481.html.
Results
KPS, TKPS and AKPS were assessed simultaneously 1600
times in a total of 306 patients. There were a mean of 5.3
(standard deviation (SD) 5.0) assessments per individual,
with median 4.0 (range 1–44). Within the same individ-
ual, the multiple performance assessments were collected
over a mean of 76 (SD 88) days, with median 49 (range
0–507). Seventy-eight percent of assessments were done
in the patient's home, 7% in an aged care facility, 5% in
another relative's home, 5% in the hospital, 4% in the
inpatient hospice unit, and 1% in another location of
care.
The baseline characteristics of the patient population are
presented in Table 2. The mean age of the study popula-
tion was 71 years, 148 (49%) were male, 190 (63%) mar-
ried, and 69 (23%) widowed. The majority (93%) had
cancer and had a primary caregiver (96%). Fourteen
patients had a MMSE score of <24; of those, 10 had an
AKPS of <60.
The profile of KPS, TKPS and AKPS scores in is shown in
Figure 1. The majority of scores centered around 50–70
(group B). Measures of central of central tendency are pre-
sented in Table 3; the median score was 60 on all three
scales.
The agreement between scores was calculated for KPS-
TKPS, KPS-AKPS and TKPS-AKPS pairings, as shown in
Table 4; relevant scatter plots are in Figure 2. These dem-
onstrate a high level of agreement between the 3 scales.
When disagreement existed, KPS scores were more com-
monly higher than the TKPS or AKPS scores; the profile of
disagreement between TKPS and AKPS was more evenly
split and nearly always confined to one level. Bland-Alt-
man plot presented in figure 3 verify these interpretations.
Disagreements tended to cluster at the mid-point and
lower potions of the scales as shown in the scatter plots of
Figure 2. The Kappa coefficient for agreement between all
KPS and TKPS measurements was 0.71 (p < 0.001),
between all KPS and AKPS measurements was 0.84 (p <
0.001), and between all AKPS and TKPS measurements
was 0.82 (p < 0.001).
Table 3: Measures of central tendency and dispersion for the KPS, TKPS and AKPS scores
N Mean Median Mode SD Min-Max
KPS 1600 59.7 60 50 15.7 10–100
TKPS 1600 59.0 60 70 17.3 10–100
AKPS 1600 58.7 60 70 17.1 10–100Page 5 of 12
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survival. For those participants who died while on the trial
(n = 232), the Spearman correlation coefficients of base-
line KPS, TKPS, and AKPS and overall survival were 0.26,
0.27, and 0.26 respectively all with p < 0.001. These posi-
tive correlations imply that when performance status
increased, survival also increased. Since palliative patients
are more likely to have poor performance status, the pre-
dictive power of the three instruments in the intermediate
(category B) and lower (category C) ranges was investi-
gated (Figures 4 and 5). For category B, all three instru-
ments clearly discriminated survival for levels 50, 60 and
70 (p < 0.001; Figure 4). For category C, only AKPS could
significantly discriminate survival based upon AKPS levels
of 30 and 40 (p = 0.026; Figure 5).
Longitudinal test-retest reliability indicates the ability to
have multiple longitudinal assessments that are sensitive
to meaningful change in the outcome. Since we would be
measuring performance status over time in the trial, this
was of considerable concern for us. KPS, TKPS, and AKPS
longitudinal curves were generated for all participants; an
example is given in Figure 6. Longitudinal trends consist-
ent with the established palliative care trajectories of ill-
ness were observed with all instruments (data not
shown). Change in performance status level was investi-
Table 4: Comparison between KPS, TKPS and AKPS scores by levels
N %
Comparison between scores for KPS and TKPS
By score
TKPS > KPS by three levels 1 0.1%
TKPS > KPS by two levels 7 0.4%
TKPS > KPS by one levels 149 9.3%
Complete agreement 1216 76.0%
TKPS < KPS by one levels 179 11.2%
TKPS < KPS by two levels 48 3.0%
TKPS < KPS by three levels 0 0.0%
By Group (ABC)
TKPS >KPS by one group 96 6.0%
Complete agreement 1489 93.1%
TKPS <KPS by one group 15 0.9%
Comparison between scores for KPS and AKPS
By score
AKPS > KPS by three levels 1 0.1%
AKPS > KPS by two levels 1 0.1%
AKPS > KPS by one levels 44 2.8%
Complete agreement 1386 86.6%
AKPS < KPS by one levels 123 7.7%
AKPS < KPS by two levels 45 2.8%
AKPS < KPS by three levels 0 0.0%
By Group (ABC)
AKPS >KPS by one group 80 5.0%
Complete agreement 1507 94.2%
AKPS <KPS by one group 13 0.8%
Comparison between scores for TKPS and AKPS
By score
TKPS > AKPS by three levels 0 0.0%
TKPS > AKPS by two levels 8 0.5%
TKPS > AKPS by one levels 139 8.7%
Complete agreement 1359 84.9%
TKPS < AKPS by one levels 88 5.5%
TKPS < AKPS by two levels 6 0.4%
TKPS < AKPS by three levels 0 0.0%
By Group (ABC)
TKPS >AKPS by one group 15 0.9%
Complete agreement 1556 97.3%
TKPS <AKPS by one group 29 1.8%Page 6 of 12
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the deteriorating phase of palliative care (n = 96). Pallia-
tive care phase is predictive of the need for palliative care
service intervention and resource utilization [19,20].
When phase deteriorated, KPS, TKPS and AKPS all
decreased by a median of 10 (range -10 to 50).
Face validity was assessed by asking nurses to indicate
which scale was easiest to use and best suited the patient
population. Nurses involved in the collection of data for
the trial were highly skilled and experienced in palliative
care with a mean length of time in nursing of 18 years
(range 6–29) with an average of 9 years (range 2–16) in
palliative care. All nurses had university qualifications; 24
of the nurses were employed at RN level 2 (consultant)
and 2 employed at RN Level 3 (consultant and manage-
rial). All 26 nurses preferred using the AKPS as they felt
that the categories were more consistent with the multiple
venues of care and different levels of interventions needed
in their current clinical practice.
Discussion
KPS is a widely used measure demonstrated to have
important correlations with both resource utilization and
prognosis at the end of life. Generating a measure of func-
tion with language that is consistent with current clinical
practice is crucial for the ongoing use of KPS. For the
measure to transcend differences in funding of healthcare
and models of service delivery, it is timely to remove spe-
cific references to the place or intensity of care and focus
on function alone.
The Thorne modification developed in the 1990's was an
important validated update, making the scale useful for
contemporary palliative home care settings, especially
hospice. The TKPS concentrated on the community set-
ting, though, limiting the scale's utility in the varied clini-
cal settings encountered in palliative care including
inpatient hospice, acute inpatient care, and nursing home
care. This is the first research report of the Australia-mod-
ified version (AKPS), an important amalgam of the origi-
nal KPS and the TKPS applicable to both inpatient and
community palliative care. The categories in the AKPS are
less directive of the expected location of care; however, as
much of the original KPS and TKPS language as possible
has been maintained in order to reduce confusion and the
need for extensive retraining for clinicians already familiar
with the earlier versions.
In this study all versions of the KPS could be used in the
various venues of palliative care including the commu-
nity, acute inpatient, subacute inpatient, inpatient hos-
pice, respite, nursing home, and hostel settings. AKPS had
the highest agreement with both KPS and TKS (Table 4,
Figures 2 and 3), and was equally predictive of survival
(Figure 4). When considering the lower end of the scale
(category C) where more palliative patients cluster, AKPS
was most predictive of survival (Figure 5). All scales were
able to reflect longitudinal change. The nurses reflected
that AKPS was easiest to use and most acceptable. This
study demonstrated that AKPS had excellent correlation
with the original KPS while allowing for palliative care
sensitive clinician responses to changes in level of func-
tion as death approaches, both in terms of place of care
and the clinical staff who need to be involved in that care.
The better performance of the AKPS will assist with better
decision-making in palliative care.
The high level of agreement among the three versions was
expected, given the similarity of the three scales. However,
before a new scale is adopted for day-to-day clinical prac-
tice it is important that it is carefully and prospectively
evaluated to ensure that the results reflect what the user
expects to be measuring. Further, as we planned to use
performance status as a primary outcome in a major clin-
ical trial in palliative care it was vital to verify the validity
of the AKPS as an outcome measure within the palliative
care setting before limiting all of our data collection to
this single measure. The need for formal validation is evi-
dent in Table 4 and Figure 2. Some participants were
assessed as a KPS of 20 and an AKPS of 50 even when the
KPS 50 and AKPS 50 had exactly the same phrasing. This
was done by the same nurse assessing the patient using
each of the scales sequentially at the same evaluation visit.
This difference in scoring was reflective of the difference in
phrasing at other levels on the scales. For an individual
palliative care patient, a score of KPS 20 ("very sick; hos-
pitalization necessary; active supportive treatment neces-
sary") may be the best option on that scale, however when
reviewing the AKPS scale the score of 50 ("requires consid-
erable assistance and frequent medical care") was more
appropriate in relation to all other levels on the scale.
Importantly, the AKPS instrument with more palliative
Profile of KPS, TKPS and AKPS scores in the 1600 observa-tionsFigure 1
Profile of KPS, TKPS and AKPS scores in the 1600 observa-
tions.
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expected overall correlation with survival, was more corre-
lated with survival at lower performance status, and was
more acceptable to the clinical nurses.
Longitudinal assessment
Any of the KPS tools provide both an objective measure of
the current status of the person being assessed and useful
trends when used longitudinally. Longitudinal trends in
performance status is an important aspect of prognostica-
tion for the longer term outlook of the patient including
his or her anticipated health resource and service needs
over time, as demonstrated by the relationship between
performance status and phase of palliative care [20]. Such
changes in level of function reflect the disease trajectories
described by Lunney, Lynn and colleagues [21], irrespec-
tive of the underlying life-limiting illness.
Bland & Altman plot for the performance status pairsFigure 3
Bland & Altman plot for the performance status pairs.
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Scatter plots of KPS-TKPS, KPS-AKPS, and AKPS-TKPS pairsFigure 2
Scatter plots of KPS-TKPS, KPS-AKPS, and AKPS-TKPS pairs.
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KPS is not the only measure of performance status used in
palliative care and oncology. The shorter Eastern Cooper-
ative Oncology Group (ECOG) performance status scale
was derived from the KPS [22]. It is only occasionally used
as a main outcome in clinical trials in the palliative care
setting since the 5-item scale inadequately differentiates
between patients with poor functional status. Similar con-
cerns about the KPS having limited sensitivity to monitor
change when patients score at the low end of the scale
have been reported by other authors [2]. In this current
study, AKPS was superior to KPS and TKPS in the lower
Survival probabilities according to KPS, TKPS and KPS by lev-els 30 and 40 (Cat gory C)Figure 5
Survival probabilities according to KPS, TKPS and KPS by lev-
els 30 and 40 (Category C).
KPS: p for difference between the levels = 0.9348
KPS Median (IQR)
40 171 (83-283)
30 156 (71-296)
TKPS: p for difference between the levels = 0.108
TKPS Median (IQR)
40 177 (70-296)
30 141 (83-229)
AKPS: p for difference between the levels = 0.026
AKPS Median (IQR)
40 183 (83-296)
30 128 (83-229)
Survival probabilities according to KPS, TKPS and KPS by lev-els 50, 60 and 70 (Categ y B)Figure 4
Survival probabilities according to KPS, TKPS and KPS by lev-
els 50, 60 and 70 (Category B).
KPS: p for difference between the levels <0.001
KPS Median (IQR)
70 229 (112-610)
60 177 (91-336)
50 137 (71-296)
TKPS: p for difference between the levels <0.001
TKPS Median (IQR)
70 207 (99-459)
60 177 (84-397)
50 153 (79-296)
AKPS: p for difference between the levels <0.001
AKPS Median (IQR)
70 229 (112-610)
60 177 (93-366)
50 112 (61-283)Page 9 of 12
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performance status than the ECOG scale.
In 1996, Anderson et al described the Palliative Perform-
ance Scale (PPS), a modification of the KPS based on 5
observable parameters (ambulation, activity combined
with evidence of disease, self-care, intake and conscious
level) scored into 11 categories. [23]. PPS predicted time
to death (mean 162 days) for a population of Australian
patients admitted to a palliative care unit[24]. PPS was not
as predictive of survival for a similar group of Japanese
palliative care patients with a mean survival of 49 days
[11]. AKPS is a less complex measure which is easier to use
with each clinical encounter.
Other scales such as the Edmonton Functional Assess-
ment Tool extend on the functional parameters described
in the KPS, PPS and TKPS [2], however as these scales and
their scoring becomes more complicated, their day-to-day
applicability decreases. AKPS focuses on current func-
tional abilities and on changes in function if used longitu-
dinally; it provides an important parameter in the overall
assessment of any person with a life-limiting illness.
Limitations
This study is representative by age and gender for pallia-
tive care in Australia. Because it was a sub-study of a larger
randomized controlled trial where pain in the previous 3
months was an inclusion criterion, the population almost
all had cancer as their life-limiting illness (92%) versus
85% seen in the general population referred to the pallia-
tive care service. Given that KPS was originally developed
for people with cancer and had been extrapolated to other
clinical settings (AIDS, end-stage organ failure), this
should not be a major limit to generalizing these findings.
In the early parts of the trial, measurement of KPS, TKPS
and AKPS was predominantly in the community setting
limiting the ability to observe its utility in other care ven-
ues. As more trial participants were hospitalized over
time, data were collected from the inpatient settings there-
fore reflecting the range of settings in which palliative care
is delivered. Many assessments were in the upper range of
the scales; only a minority of patients were bedridden. An
evaluation on a palliative care unit with more severely dis-
abled patients might show other results. The missing cor-
relation of KPS and TKPS with survival in the lower range
of the scale may have been biased by small patient num-
bers in these clusters. Also, ideally none of the perform-
ance status measures would have any reference to the
amount of health services required at any of the levels.
AKPS has considerably less reference, but still states
"requires... frequent medical care" in its description of
AKPS 50.
Inter-rater reliability evaluation of the AKPS was originally
planned as part of this sub-study. Ill palliative care
patients were overly burdened by multiple visits on the
same day for research data collection. An alternative plan
was enacted with collection of measures after the
informed consent document was signed and then com-
paring these results with those reported on the baseline
assessment within 48 hours of the consent visit. Unfortu-
nately many patients were too unstable or the timing of
the baseline assessment was too far from the consent visit;
there were not enough data available for these analyses.
The inter-rater reliability and other psychometric proper-
ties of the KPS has previously been documented[3,6,7]. As
AKPS was more predictive of survival outcomes than KPS,
the reliability was expected to be better if it differed from
that reported for the KPS.
In addition to being more predictive of survival at the
lower end of the scale, the AKPS may be more appropriate
than the other performance status scales in settings out-
side of cancer. Ninety-two percent of participants in this
study had cancer, so evaluation of the AKPS in non-cancer
diagnoses was limited. Further work should concentrate
on disabled palliative care patients whose performance
status is at the lower end of the scale. Future studies will
focus on validity outside of the cancer setting and with
more diverse palliative care populations. Also, the per-
formance of the AKPS will be compared to other perform-
ance status measurement tools appropriate for palliative
care such as the ECOG scale, PPS and Edmonton Func-
tional Assessment Tool.
Conclusion
The AKPS is an important contemporary modification to
the KPS that incorporates language more appropriate to
current clinical care without limiting it to judgments on
Demonstration of the ability of the three instruments to respond to change in performance status ove  timeFigure 6
Demonstration of the ability of the three instruments to 
respond to change in performance status over time. Plots 
nearly overly each other. Similar plots were generated for all 
participants.
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AKPS assists with clinical decision-making across a range
of clinical settings. The ability of staff to relate to the per-
formance status scale used will continue to be a key factor
in uptake and use of a measure that has such broad appli-
cation. It is appropriate to use the AKPS as a primary out-
come variable in the Palliative Care Trial.
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